jueves, 21 de julio de 2016

ESMO 2018 Annual Congress to be held in Munich

ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO 2018 Annual Congress will take place between 19-23 October 2018 at the Messe Muenchen, Germany.
The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate such progress into better cancer patient care.
“Germany has a long-standing tradition of active participation in ESMO’s activities. This is witnessed by the high number of German members, ranking third after the USA and Italy, as well as their ever growing attendance at our events,” says ESMO President Fortunato Ciardiello. “Our German colleagues cover many seats in various ESMO committees, in the ESMO Faculty as well as on the ESMO Executive Board, demonstrating the contribution Germany makes to the oncology field and to ESMO. I am pleased that Germany – and in particular Munich, will be our destination in 2018.”
ESMO Munich 2018 will be the second time that an ESMO Congress has taken place in Germany. The previous German congress was held in Hamburg in the year 2000.
“It is my great pleasure to welcome ESMO in Munich for the ESMO 2018 Congress,” says Carsten Bokemeyer, President of the German Society of Hematology and Medical Oncology (DGHO). “During the last few years we have achieved a lot in the diagnosis and treatment of cancer, which has generated an impressive flood of data. How do we deal with this? How do we interpret data in the context of clinical issues? These are important questions which emphasise the importance of exchange between the fields of basic and translational research and clinical care of patients with cancer, on a European scale.”
“We are very proud and delighted that in 2018 colleagues from all over the world will attend the ESMO Congress in Germany to share their knowledge and learn from each other in order to improve cancer patient care in Europe and beyond,” says Bokemeyer.
The programme of the ESMO 2018 congress will be developed by a committee composed of more than 300 international experts under the leadership of Prof Solange Peters, Head of Medical Oncology at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. “I feel honoured to have been selected to lead the Scientific Committee of the ESMO 2018 Congress, and for being the second ever female Scientific Committee Chair, after Prof Martine Piccart in 2012,” she says.
“I am confident that we have built an exceptional team that will develop a remarkable programme, meeting the high expectations of attendees coming from all over the world wanting to learn state-of-the-art oncology, hear the hottest results and, most important, be guided by reliable experts to transform the incredible amount of information into recommendations for daily clinical practice,” she concludes.
Nearly 20,000 oncology stakeholders from over 130 countries worldwide are expected to attend the ESMO 2018 Congress in Munich, making this one of the largest medical events ever hosted by the Bavarian city.
Dr. Reinhard Pfeiffer, Deputy CEO Messe München, with responsibility for congress business says:
“The city of Munich and Messe München are delighted to host ESMO 2018. Munich is a thriving centre for science, research and education and an outstanding congress destination. Being a “Weltstadt mit Herz - metropolis with a heart” Munich will do a perfect job in combining the professionalism of a scientific centre with culture and hospitality. As Messe München we are helping to ensure the success of this congress by providing a high-tech congress and exhibition centre and specialist services. We will all be working together to ensure delegates take home positive impressions of Munich!” 
ESMO is the European leading force of high-quality oncology education. The ESMO Annual Congress offers a platform for international visibility for oncology research, directly contributing to continuous improvements in cancer patient care.